EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
| العنوان: | EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands |
|---|---|
| المؤلفون: | Katarina Sjögreen Gleisner, Nicolas Chouin, Pablo Minguez Gabina, Francesco Cicone, Silvano Gnesin, Caroline Stokke, Mark Konijnenberg, Marta Cremonesi, Frederik A. Verburg, Peter Bernhardt, Uta Eberlein, Jonathan Gear |
| المساهمون: | Radiology & Nuclear Medicine |
| المصدر: | Addi. Archivo Digital para la Docencia y la Investigación instname European Journal of Nuclear Medicine and Molecular Imaging, 49(6), 1778-1809. Springer-Verlag European journal of nuclear medicine and molecular imaging, vol. 49, no. 6, pp. 1778-1809 |
| بيانات النشر: | Springer, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Radioisotopes, somatostatin-receptor ligands, prostate adenocarcinoma, dosimetry, General Medicine, Lutetium, Prostate-Specific Antigen, Ligands, PSMA-targeting ligands, Humans, neuroendocrine, Radiology, Nuclear Medicine and imaging, Receptors, Somatostatin, Lutetium/therapeutic use, Radiation Injuries, Radiopharmaceuticals/adverse effects, Somatostatin, Dosimetry, Lutetium-177, Neuroendocrine, Prostate adenocarcinoma, Somatostatin-receptor ligands, Radiopharmaceuticals |
| الوصف: | [EN] The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA. Open access funding provided by Lund University. Economic support was granted by the Swedish Cancer Society (180747, 211754Pj01H) and Mrs. Berta Kamprad's Foundation (BKS-2020-13) (Sjogreen Gleisner). |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1619-7070 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ace0d1afc90bbb37e1345267d5a7180 http://hdl.handle.net/10810/56463 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....7ace0d1afc90bbb37e1345267d5a7180 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 16197070 |
|---|